• Healio joins Cleveland Clinic’s A.I. Summit as official media partner
    Friday, July 11, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    Healio announced an official media partnership with the Cleveland Clinic’s A.I. Summit for Healthcare Professionals, where Healio will unveil OncoIntel, a new tool for hematology and oncology HCPs that is set to launch this fall....
  • No cancer risk with long-term ixekizumab for psoriatic diseases
    Friday, July 11, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    Incidences of malignant neoplasms were low and stable with long-term ixekizumab treatment for people with psoriatic disease and axial spondyloarthritis, according to findings from a pooled analysis. Chronic inflammation seen in psoriasis...
  • FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer
    Friday, July 11, 2025 from ESMO News
    Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies
  • Details of Julian McMahon’s cancer revealed a week after his death aged 56
    Thursday, July 10, 2025 from Cancer | The Guardian
    Charmed, Fantastic Four and Nip/Tuck actor’s cause of death was lung metastasis due to head and neck cancer Julian McMahon – a life in pictures Julian McMahon’s cause of death has been revealed, a little over a week after the Australian...
  • High-cost immunotherapy increases likelihood of financial hardship among cancer survivors
    Thursday, July 10, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    Cancer survivors who received high-cost immunotherapies appear more likely to experience financial hardship, according to study results published in Journal of Cancer Survivorship. Financial hardship, including debt, inability to afford...
  • HHS cancels USPSTF meeting, raising concern among medical groups
    Thursday, July 10, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    HHS abruptly canceled a U.S. Preventive Services Task Force meeting scheduled for today, leading some to question the future of its 16 members. HHS confirmed the cancelation to Healio but did not comment on whether the meeting would be...
  • 'We need to keep up': How PCPs can fight the rising tide of early-onset colorectal cancer
    Thursday, July 10, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    As early-onset colorectal cancer cases rise, primary care providers can help young patients identify the first symptoms and save lives with timely screening, according to experts. Cases of early-onset colorectal cancer (CRC) are climbing...
  • Monarez a step closer to becoming CDC director
    Wednesday, July 9, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    Senators voted along party lines Wednesday to advance the nomination of Susan Monarez, PhD, to be the next CDC director. The Senate’s Health, Education, Labor and Pensions (HELP) committee voted 12-11 in favor of sending the nomination...
  • AI model detects delirium among hospitalized older adults
    Wednesday, July 9, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    An AI model designed to automate assessment of delirium risk increased the number of detected cases among hospitalized older adults, according to results of a quality improvement study. Use of the model, which alerts trained team members...
  • 6 questions physicians should ask before buying an AI product
    Wednesday, July 9, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    More physicians than ever are turning to AI to improve efficiency — from administrative tasks to diagnosis and treatment — but it is important to do due diligence and fully understand an AI product before implementing it, experts said....
  • Expert: Antimicrobial resistance is a ‘cancer care crisis’
    Wednesday, July 9, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    Many antimicrobial resistant pathogens are more prevalent in patients with cancer than in those without, even in the outpatient setting. A retrospective analysis found outpatients with cancer had higher prevalence of several WHO...
  • NHS pharmacies to pilot ‘sponge on a string’ test to spot cancer precursor
    Wednesday, July 9, 2025 from Cancer | The Guardian
    Scheme in England to identify signs of oesophageal cancer forms part of government’s 10-year health plan Hundreds of people in England are to be offered a “sponge on a string” test to identify a precursor to one of the deadliest cancers...
  • FDA approves SIR-Spheres for unresectable hepatocellular carcinoma
    Tuesday, July 8, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    The FDA approved Y-90 resin microspheres for the treatment of unresectable hepatocellular carcinoma, according to a press release from the manufacturer. Y-90 resin microspheres (SIR-Spheres, Sirtex Medical) are a medical device...
  • ‘Healthy food matters’: Food insecurity increases mortality risk for cancer survivors
    Tuesday, July 8, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    Patients with cancer who experience food insecurity have a significantly higher risk for death than those who have greater access to nutritional meals, according to results of a quantitative analysis. Food insecurity had a significant...
  • ‘Not just a physical issue’: CRC linked to adverse sexual health outcomes among women
    Tuesday, July 8, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    Women with colorectal cancer appear to have higher risk for dyspareunia, pelvic inflammatory disease, endometriosis and premature ovarian failure compared with those without cancer, according to study results. These findings, published...
  • Private equity groups significantly raise colonoscopy prices at practices they acquire
    Tuesday, July 8, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    Colonoscopy prices have increased significantly more at private equity-acquired gastroenterology practices compared with those at independent ones, according to results of a retrospective analysis. However, the quality of care remains...
  • Molecular profiling may aid adjuvant radiotherapy approach for endometrial cancer
    Monday, July 7, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    Molecular profiling could reduce both overtreatment and undertreatment of patients with high-intermediate risk endometrial cancer, according to findings presented at ESTRO 2025. Results of a randomized phase 3 trial showed many women...
  • Is exercise really better than drugs for cancer remission? It's an appealing idea – but it's misleading | Devi Sridhar
    Friday, July 4, 2025 from Cancer | The Guardian
    The healing power of exercise should never be underestimated, but be cautious about what recent headlines seem to suggest Prof Devi Sridhar is chair of global public health at the University of Edinburgh, and the author of How Not to Die...
  • Trump signs 'Big Beautiful Bill': Here's what it means for health care
    Thursday, July 3, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    The House has passed the Trump administration’s sweeping domestic agenda bill, which experts said will have massive implications for health care in the United States. The legislation, known as the “Big Beautiful Bill,” was signed into...
  • AI diagnostic superiority over physicians may be ’exaggerated’
    Thursday, July 3, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    When Microsoft AI announced one of its systems solved complex medical cases more accurately and cost-effectively than expert physicians, the company touted the results as a first step on the “path to medical superintelligence.” Health...
  • Federal judge blocks mass layoffs at HHS
    Thursday, July 3, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    A federal judge this week granted a preliminary injunction to halt mass layoffs at HHS, saying the Trump administration was not authorized to make sweeping changes to an agency created by Congress. The decision, handed down by U.S....
  • Q&A: An interview with the hosts of ‘This Podcast Will Kill You’
    Thursday, July 3, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    PHOENIX — The hosts of “This Podcast Will Kill You” encouraged attendees at this year’s Association for Professionals in Infection Control and Epidemiology meeting to become better science communicators. Erin Allmann Updyke, MD, PhD,...
  • Long-term blood pressure lowering does not appear to impact risk for new-onset cancer
    Thursday, July 3, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    Long-term antihypertensive therapy was not associated with risk for cancer, cancer-related mortality or site-specific cancers of any type, according to study findings. Using data from more than 300,000 participants in 42 randomized...
  • The French paradox: Lessons for American practice management
    Thursday, July 3, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    “There is nothing so useless as doing efficiently that which should not be done at all.” – Peter Drucker “There’s a way to do it better — find it.” – Thomas A. Edison We recently finished a small consulting project in a suburban Paris...
  • Sweet-smelling molecule halts therapy-resistant pancreatic cancer
    Thursday, July 3, 2025 from Cancer News -- ScienceDaily
    A compound best known for giving almonds and apricots their aroma may be the key to defeating hard-to-kill cancer cells. Japanese researchers found that benzaldehyde can stop the shape-shifting ability of aggressive cancer cells, which...
  • The fatal mutation that lets cancer outsmart the human immune system
    Wednesday, July 2, 2025 from Cancer News -- ScienceDaily
    Scientists at UC Davis discovered a small genetic difference that could explain why humans are more prone to certain cancers than our primate cousins. The change affects a protein used by immune cells to kill tumors—except in humans,...
  • Air pollution linked to lung cancer-driving DNA mutations, study finds
    Wednesday, July 2, 2025 from Cancer | The Guardian
    Research finds that the higher the levels of air pollution in a region, the more cancer-promoting mutations are present Air pollution has been linked to a swathe of lung cancer-driving DNA mutations, in a study of people diagnosed with...
  • Women over 65 still at risk from cancer from HPV and should be offered cervical screening – study
    Tuesday, July 1, 2025 from Cancer | The Guardian
    Cases of cervical cancer among older people rising globally as research finds over-65s more likely to have HPV infections than younger women Routine cervical screening should be offered to women aged 65 and over as they are still at...
  • This virus infects millions—and we just discovered its secret weapon
    Monday, June 30, 2025 from Cancer News -- ScienceDaily
    Scientists have discovered a stealthy mechanism that cytomegalovirus (CMV)—the leading infectious cause of birth defects in the U.S.—uses to infiltrate blood vessel cells while evading immune detection. The virus forms a hidden protein...
  • [Articles] Hormone therapy use and young-onset breast cancer: a pooled analysis of prospective cohorts included in the Premenopausal Breast Cancer Collaborative Group
    Monday, June 30, 2025 from The Lancet Oncology
    Oestrogen hormone therapy use was inversely associated with young-onset breast cancer, and oestrogen plus progestin hormone therapy was associated with higher young-onset breast cancer incidence among women with intact uterus and...
  • [Correspondence] Bridging tumour classification and treatment
    Monday, June 30, 2025 from The Lancet Oncology
    We read with great interest Jennelle C Hodge and colleagues’ Comment on the WHO Classification of Tumours1 and wish to highlight the crucial need to bridge the growing gap between diagnostic classification and therapeutic access in the...
  • [Correspondence] Considerations for results of the patient-reported outcome analyses of the TALAPRO-2 trial
    Monday, June 30, 2025 from The Lancet Oncology
    Nobuaki Matsubara and colleagues1 and Andre P Fay and colleagues2 are to be congratulated for making the patient perspective an integral part of cancer drug development with patient-reported outcomes from the TALAPRO-2 trial.
  • [Correspondence] Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors
    Monday, June 30, 2025 from The Lancet Oncology
    The 50-month follow-up of LITESPARK-004, reported by Ramaprasad Srinivasan and colleagues,1 marks a pivotal advance for von Hippel-Lindau disease, a rare syndrome with limited therapies. The findings on belzutifan's durable efficacy,...
  • [Correspondence] Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors
    Monday, June 30, 2025 from The Lancet Oncology
    Ramaprasad Srinivasan and colleagues described good oncological outcomes coupled with acceptable toxicity following treatment with the hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan for patients with von Hippel-Lindau...
  • [Correspondence] Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors – Authors' reply
    Monday, June 30, 2025 from The Lancet Oncology
    We thank the authors of these Correspondence pieces for their interest in our Article.1
  • [Corrections] Correction to Lancet Oncol 2024; 25: 1614–24
    Monday, June 30, 2025 from The Lancet Oncology
    Hughes T, Harper A, Gupta S, et al. The current and future global burden of cancer among adolescents and young adults: a population-based study. Lancet Oncol 2024; 25: 1614–24—In this Article, figure 3 has been replaced with an updated...
  • [Corrections] Correction to Lancet Oncol 2025; 26: e46–54
    Monday, June 30, 2025 from The Lancet Oncology
    Romero Y, Tittenbrun Z, Trapani D, et al. The changing global landscape of national cancer control plans. Lancet Oncol 2025; 26: e46–54—In this Policy Review, the spelling of Maha Al-Ghafry's name was incorrect in the NCCP Global Review...
  • [Corrections] Correction to Lancet Oncol 2025; 26: 503–15
    Monday, June 30, 2025 from The Lancet Oncology
    Van Gorp T, Moore KN, Konecny GE, et al. Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a...
  • [Corrections] Correction to Lancet Oncol 2025; 26: 571–82
    Monday, June 30, 2025 from The Lancet Oncology
    Srinivasan R, Iliopoulos O, Beckermann KE, et al. Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study. Lancet Oncol 2025; 26:...
  • [Corrections] Correction to Lancet Oncol 2025; 26: e320–30
    Monday, June 30, 2025 from The Lancet Oncology
    Villarreal-Garza C, Aranda-Gutierrez A, Gonzalez-Sanchez DG, et al. National cancer control plans in Latin America and the Caribbean: challenges and future directions. Lancet Oncol 2025; 26: e320–30—In this Policy Review, the spelling of...
  • [Corrections] Correction to Lancet Oncol 2025; 26: 924–35
    Monday, June 30, 2025 from The Lancet Oncology
    Reddy CL, Sousa C, Atun R. Benchmarking infrastructure for cancer control in Commonwealth countries: a population-based observational study. Lancet Oncol 2025; 26: 924–35—In this Article, Prof Rifat Atun should have had the additional...
  • [Perspectives] Solutions for tackling the global surgery crisis in west Africa
    Monday, June 30, 2025 from The Lancet Oncology
    The global surgical crisis has become one of the most discussed health topics since the Lancet Commission report published in 2015 because the need is massive, and the consequences are devastating both to countless personal lives and to...
  • [Perspectives] You are her son, not her doctor
    Monday, June 30, 2025 from The Lancet Oncology
    It was by far the most difficult phone call of my life. Absolutely nothing can prepare you for telling your mother that she has stage 4 lung cancer. One does not need to understand the intricacies of cancer staging to feel the gravity of...
  • [Correspondence] Overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy
    Monday, June 30, 2025 from The Lancet Oncology
    The results of the dose-expansion portion of our multicentre, open-label, phase 1b study evaluating the combination of gedatolisib, a pan-PI3K–mTORC1/2 inhibitor, with palbociclib and endocrine therapy in patients with hormone...
  • [Correspondence] RADIOSA and the management of oligorecurrent prostate cancer: a step forward, but the journey continues
    Monday, June 30, 2025 from The Lancet Oncology
    The RADIOSA phase 2 randomised clinical trial included 102 patients with metachronic oligometastic prostate cancer who were randomly assigned to receive either stereotactic body radiotherapy (SBRT) with 6 months of androgen deprivation...
  • [Correspondence] RADIOSA and the management of oligorecurrent prostate cancer: a step forward, but the journey continues
    Monday, June 30, 2025 from The Lancet Oncology
    We read with great interest the published results of the RADIOSA trial by Giulia Marvaso and colleagues.1 This well designed randomised phase 2 study represents an important effort in addressing the role of stereotactic body radiotherapy...
  • [Correspondence] SANO trial: innovations, risks, and unanswered questions
    Monday, June 30, 2025 from The Lancet Oncology
    We read the published Article by Berend J van der Wilk and colleagues reporting the results of the SANO trial with great interest as it reveals many crucial questions regarding the optimal treatment of patients with resectable...
  • [Correspondence] SANO trial: innovations, risks, and unanswered questions
    Monday, June 30, 2025 from The Lancet Oncology
    The validity of the SANO trial hinges on a single premise: the procedure for monitoring complete clinical response is reliable.1 Every patient randomly assigned to surgery was first confirmed to have a complete clinical response by the...
  • [Correspondence] SANO trial: innovations, risks, and unanswered questions
    Monday, June 30, 2025 from The Lancet Oncology
    Despite the obvious interest in an organ preservation strategy for oesophageal cancer, the SANO trial, published in the report by Berend J van der Wilk and colleagues,1 has important limitations, which must be carefully considered in the...
  • [Correspondence] SANO trial: innovations, risks, and unanswered questions
    Monday, June 30, 2025 from The Lancet Oncology
    The SANO study by Berend J van der Wilk and colleagues showed non-inferiority of the non-surgical approach if complete clinical response was reached with chemoradiation in patients with resectable oesophageal squamous cell carcinoma.1 We...
  • Powered by Feed Informer